Identification of a better Homo sapiens Class II HDAC inhibitor through binding energy calculations and descriptor analysis

BMC Bioinformatics

Volumn 11, Issue SUPPL. 7, 2010, Pages

  Tambunan, Usman S F ^a   Wulandari, Evi K ^a  

^a UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

ENERGY CALCULATION; HISTONE DEACETYLASE INHIBITOR; HISTONE DEACETYLASES; HUMAN PAPILLOMA VIRUS; HUMAN PAPILOMAVIRUS; ORAL BIOAVAILABILITIES; PHARMACOLOGICAL PROPERTIES; POTENTIAL INHIBITORS; , INHIBITOR; ACTIVE SITE; BINDING AFFINITIES; CANCER CELLS; CARBONYL GROUPS; CERVICAL CANCERS; CLASS I; CLASS II; CYTOTOXIC; DESCRIPTORS; DRUG SCORE; DRUG TARGETS; GROWTH ARREST; HDAC INHIBITORS; HOMO SAPIENS; ZINC IONS;

BIOCHEMISTRY; CARBONYL COMPOUNDS; CELL DEATH; ENZYME INHIBITION; VIRUSES; ZINC; BINDING ENERGY;

BINDING ENERGY; BIOINFORMATICS;

HOMO SAPIENS; HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CHEMICAL MODEL; CHEMISTRY; DRUG EFFECT; GEL CHROMATOGRAPHY; HUMAN; LD 50; METABOLISM; MOUSE; PROTEIN BINDING; RAT; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CHROMATOGRAPHY, GEL; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; LETHAL DOSE 50; MICE; MODELS, CHEMICAL; PROTEIN BINDING; RATS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 77957920371     PISSN: None     EISSN: 14712105     Source Type: Journal    
DOI: 10.1186/1471-2105-11-S7-S16     Document Type: Article

References (23)

1. Parkin DM. The global health burden of infection-associated cancers in the year. Int J Cancer 2006, 118:3030-3044. 10.1002/ijc.21731, 16404738.
2. Lowndes CM. Vaccines for cervical cancer. Epidemiol Infect 2006, 134:1-12,. 10.1017/S0950268805005728, 2870376, 16409645.
3. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997, 102:3-8. 10.1016/S0002-9343(97)00177-0, 9217656.
4. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Current Cancer Drug Targets 2007, 7:79-89. 10.2174/156800907780006869, 17305480.
5. Kalvatchev Z, Rösl F. Human papilloma viruses: realities and perspectives. Biotechnol Biotechnol Equip 2007, 24:137-143.
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
7. Bosch FX, Manos MM, Muñoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papilomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87:796-802. 10.1093/jnci/87.11.796, 7791229.
8. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code. Ann N Y Acad Sci 2003, 983:84-100. 10.1111/j.1749-6632.2003.tb05964.x, 12724214.
9. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003, 370:737-49. 10.1042/BJ20021321, 1223209, 12429021.
10. Subha K, Kumar GR. Assessment for the identification of better HDAC inhibitor class through binding energy calculations and descriptor analysis. Bioinformation 2008, 3:218-222. 2646192, 19255637.
11. Finzer P, Kuntzen C, Soto U, zur Hausen H, Rösl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 2001, 20:4768-76. 10.1038/sj.onc.1204652, 11521189.
12. Finzer P, Ventz R, Kuntzen C, Seibert N, Soto U, Rösl F. Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression. Virology 2002, 304:265-73. 10.1006/viro.2002.1667, 12504567.
13. Finzer P, Krueger A, Stöhr M, Brenner D, Soto U, Kuntzen C, Krammer PH, Rösl F. HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway. Oncogene 2004, 23:4807-17. 10.1038/sj.onc.1207620, 15077164.
14. Acharya MR, Sparreboom A, Sausville EA, Conley BA, Doroshow JH, Venitz J, Figg WD. Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor. Cancer Chemother Pharmacol 2006, 57:275-81. 10.1007/s00280-005-0058-8, 16028097.
15. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994, 22:4673-80. 10.1093/nar/22.22.4673, 308517, 7984417.
16. Martí-Renom MA, Stuart AC, Fiser A, Sánchez R, Melo F, Sali A. Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 2000, 29:291-325. 10.1146/annurev.biophys.29.1.291, 10940251.
17. Hildebrand A, Remmert M, Biegert A, Söding J. Fast and accurate automatic structure prediction with HHpred. Proteins 2009, 77(Suppl 9):128-32.
18. Dolinsky TJ, Czodrowski P, Li H, Nielsen JE, Jensen JH, Klebe G, Baker NA. PDB2PQR: expanding and upgrading automated preparation of biomolecular structures for molecular simulations. Nucleic Acids Res 2007, 35:W522-5. 10.1093/nar/gkm276, 1933214, 17488841.
19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46:3-26. 10.1016/S0169-409X(00)00129-0, 11259830.
20. Willard L, Ranjan A, Zhang H, Monzavi H, Boyko RF, Sykes BD, Wishart DS. VADAR: a web server for quantitative evaluation of protein structure quality. Nucleic Acids Res 2003, 31:3316-9. 10.1093/nar/gkg565, 168972, 12824316.
21. Bottomley MJ, Lo Surdo P, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, Jones P, Neddermann P, De Francesco R, Steinkühler C, Gallinari P, Carfí A. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 2008, 283:26694-704. 10.1074/jbc.M803514200, 18614528.
22. Schuetz A, Min J, Allali-Hassani A, Schapira M, Shuen M, Loppnau P, Mazitschek R, Kwiatkowski NP, Lewis TA, Maglathin RL, McLean TH, Bochkarev A, Plotnikov AN, Vedadi M, Arrowsmith CH. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J Biol Chem 2008, 283:11355-63. 10.1074/jbc.M707362200, 2431080, 18285338.
23. Wang DF, Helquist P, Wiech NL, Wiest O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J Med Chem 2005, 48:6936-47. 10.1021/jm0505011, 16250652.